Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

NCT01605227 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1028

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer
Castration Resistant Prostate Cancer
Pain
Prostatic Neoplasms

Interventions

DRUG: cabozantinib
DRUG: prednisone

Sponsor

Exelixis